Retatrutide, a triple agonist that engages the GIP, GLP-1, and glucagon receptors, produced 28.3 percent average weight loss at 80 weeks in its pivotal Phase 3 trial, the largest reduction yet reported in a Phase 3 obesity study, and a figure that approaches the range of bariatric surgery
Ozempic, with its active ingredient semaglutide, was initially approved for managing type 2 diabetes
If used, multi use charger must have the capability to be set to LiPo or Lithium Polymer
What the April 30 Notice Actually Says On April 30, 2026, the FDA published a Federal Register notice (Docket FDA-2018-N-3240, Federal Register document 2026-08552) proposing to exclude three GLP-1 receptor agonists from the 503B Bulks List the list of bulk drug substances for which FDA has determined there is a clinical need permitting outsourcing facility compounding from raw active pharmaceutical ingredient
10 pounds down in the first month!" "its been a smooth process" "Ive tried every diet under the sun, but this is the ONLY thing thats ever worked
